According to Jefferies, Orthofix Int'l OFIX posted an overall in-line quarter, as weakness in spine stimulation was offset by upside in orthopedics.
Jefferies said that the company announced significant progress toward settlement with the spine stimulation DOJ and FCPA investigations, which have been notable overhangs on OFIX shares. “With continued operating profitability improvement, we maintain our Buy rating.”
Orthofix closed yesterday at $33.74.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsHealth CareHealth Care EquipmentJefferiesOrthofix International
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in